These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12894184)

  • 1. Illumina tussles in court with ABI.
    Powell K
    Nat Biotechnol; 2003 Aug; 21(8):836-7. PubMed ID: 12894184
    [No Abstract]   [Full Text] [Related]  

  • 2. The public-private structure of intellectual property ownership in agricultural biotechnology.
    Graff GD; Cullen SE; Bradford KJ; Zilberman D; Bennett AB
    Nat Biotechnol; 2003 Sep; 21(9):989-95. PubMed ID: 12949559
    [No Abstract]   [Full Text] [Related]  

  • 3. Exiting this year and into the next.
    Nat Biotechnol; 2005 Dec; 23(12):1451. PubMed ID: 16333272
    [No Abstract]   [Full Text] [Related]  

  • 4. Selling out.
    Martin JF
    Nat Biotechnol; 2010 Apr; 28(4):315-7. PubMed ID: 20383912
    [No Abstract]   [Full Text] [Related]  

  • 5. US court case to define EST patentability.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):513. PubMed ID: 15877055
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiinfective biotechs face partnering gap.
    Sheridan C
    Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
    [No Abstract]   [Full Text] [Related]  

  • 7. Reverse mergers attract top-tier biotechs in sluggish IPO market.
    Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):598-9. PubMed ID: 16763574
    [No Abstract]   [Full Text] [Related]  

  • 8. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 9. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 11. Splurge or merge?
    Jacobs T
    Nat Biotechnol; 2003 May; 21(5):485. PubMed ID: 12721563
    [No Abstract]   [Full Text] [Related]  

  • 12. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 13. China steps towards international M&A.
    Jia H; Louët S
    Nat Biotechnol; 2005 Feb; 23(2):159. PubMed ID: 15696134
    [No Abstract]   [Full Text] [Related]  

  • 14. Protecting innovation in biotechnology startups.
    Steffe EK; Shea TJ
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE51-3. PubMed ID: 12874982
    [No Abstract]   [Full Text] [Related]  

  • 15. Equivalents in biotechnology patents.
    Auer HE
    Nat Biotechnol; 2003 Mar; 21(3):329-31. PubMed ID: 12610574
    [No Abstract]   [Full Text] [Related]  

  • 16. The importance of getting inventorship right.
    Sheiness D; Canady K
    Nat Biotechnol; 2006 Feb; 24(2):153-4. PubMed ID: 16465154
    [No Abstract]   [Full Text] [Related]  

  • 17. Brussels takes EU states to court over biopatent law.
    Habeck M
    Nat Biotechnol; 2003 Sep; 21(9):960. PubMed ID: 12949544
    [No Abstract]   [Full Text] [Related]  

  • 18. Is the viability of the Lilly doctrine on the decline?
    Walker BW; Carty SM
    Nat Biotechnol; 2003 Aug; 21(8):943-4. PubMed ID: 12894207
    [No Abstract]   [Full Text] [Related]  

  • 19. Determining the meaning of claim terms.
    Auer HE
    Nat Biotechnol; 2006 Jan; 24(1):41-3. PubMed ID: 16404391
    [No Abstract]   [Full Text] [Related]  

  • 20. Ownership at too high a price?
    Nat Biotechnol; 2003 Sep; 21(9):953. PubMed ID: 12949537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.